In conversations about medical cannabis, THC is often described as the “psychoactive” compound and CBD as the “medical” one. This is an oversimplification. They are different molecules with distinct pharmacology, while the body produces its own signaling molecules called endocannabinoids. Understanding cannabis requires understanding all three.
The body came first
Humans did not develop CB1 and CB2 receptors in order to respond to the cannabis plant. These receptors are part of an internal signaling network. Two key substances made by the body are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Together with their receptors and the enzymes that synthesize and degrade them, these make up central components of the endocannabinoid system (ECS).
Why is anandamide called the “bliss molecule”?
The name comes from the Sanskrit word ananda, meaning bliss. But anandamide is not simply a chemical that makes people happy. It participates in nerve signaling, pain, stress responses, appetite, reproduction and other functions.
Unlike many neurotransmitters that are stored in vesicles, endocannabinoids are often produced on demand and broken down relatively quickly. This helps create local, finely timed signals rather than constant activation throughout the body.
THC: a partial mimic
Δ9-tetrahydrocannabinol (THC) has sufficient affinity for CB1 and CB2 to activate these receptors as a partial agonist. At CB1 in the brain, activation can alter neurotransmitter release and affect pain, appetite, nausea, memory, time perception, emotion and coordination.
Why can THC cause a “high”?
CB1 is widespread in the central nervous system. THC delivered from outside the body can activate many receptors in a pattern and duration that differ from the ECS's local signaling. Although the receptors are the same, the location and timing of activation are different.
Imagine a house with sophisticated lighting: the ECS switches individual lights on and off when necessary. THC can sometimes switch on the lights in several rooms at once. This comparison helps explain why taking THC is not the same as producing anandamide naturally.
CBD is a different story
Cannabidiol (CBD) is not merely “THC without intoxication.” Its affinity for the classic active sites of CB1 and CB2 is relatively low, and it does not behave like THC as a conventional agonist of these receptors.
Instead, research has examined numerous biological targets, including TRPV1, 5-HT1A, GPR55, PPARγ, adenosine-related signaling and allosteric modulation of CB1. “Allosteric” means a compound may alter how a receptor responds to another signal without activating it in the same way as THC.
Why “CBD activates CB2” is too simplistic
This claim appears frequently in popular descriptions of cannabis, but it does not represent CBD pharmacology accurately. CBD can influence ECS-related processes without simply acting like a key turning on CB2. Its interactions with multiple systems are part of what makes it scientifically interesting.
THC and CBD are not simply opposites
“THC is bad and CBD is good” is just as misleading. THC-containing products have recognized or investigated medical uses involving nausea, appetite, muscle spasticity and certain pain conditions. CBD is not free of risks and is not appropriate for everyone.
CBD can raise liver enzyme levels and interact with other medications. These risks are particularly relevant at higher therapeutic doses, but lower doses are not necessarily risk-free. THC and CBD may also influence each other's effects, but natural does not mean risk-free.
Does CBD cancel the effects of THC?
Not as a universal rule. CBD may modify some THC effects under particular conditions, but the outcome depends on dose, the THC:CBD ratio, administration route, timing and individual biology. Two cannabis products with equal THC amounts can therefore produce very different experiences.
What about the “entourage effect”?
The entourage effect is the idea that cannabinoids and other plant components, including terpenes, may interact to shape the overall response. This is a plausible and active research topic, not a clinically proven rule for every condition. Some marketing claims go beyond the evidence currently available.
Why the THC:CBD ratio matters
A high-THC, low-CBD product is not equivalent to one with the reverse ratio. THC-rich preparations tend to have stronger CB1-mediated and intoxicating effects; CBD-rich preparations may feel different. But the ratio alone is insufficient: 5 mg of THC is not equivalent to 20 mg, even at the same ratio.
Why the method of administration matters
Inhaled THC generally reaches the bloodstream more rapidly than swallowed THC. After oral administration, the liver converts some THC to the active metabolite 11-hydroxy-THC. The onset, intensity and duration of effects can therefore differ substantially.
Asking “How much THC do you use?” without knowing the product, delivery method, frequency and CBD ratio misses crucial information.
Are there other cannabinoids?
Yes. Cannabis contains other cannabinoids, including CBG, CBC, CBN and THCV. Research is expanding, but THC and CBD have been studied in humans much more extensively than most minor cannabinoids. Definitive health claims for less-studied compounds deserve particular caution.
Key takeaways
- Endocannabinoids: substances the body produces, such as AEA and 2-AG.
- Phytocannabinoids: plant-derived molecules such as THC and CBD.
- Synthetic cannabinoids: artificially manufactured compounds, which may differ substantially in action and risk.
THC acts comparatively directly at CB1 and CB2. CBD has a more complex profile across multiple targets. Endocannabinoids are part of the body's own signaling and regulatory network.
Instead of asking only “What does cannabis do?”, ask: which cannabinoid, at what dose, by which route, affecting which system, in which person?
Scientific sources
- Stella N. THC and CBD: Similarities and differences between siblings. Neuron. 2023.
Find this source ↗ - Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of THC, CBD and THCV.
Find this source ↗ - Research and Clinical Practice Involving the Use of Cannabis Products, with Emphasis on Cannabidiol.
Find this source ↗ - Review of the Endocannabinoid System.
Find this source ↗ - CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions.
Find this source ↗ - Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs.
Find this source ↗
Ask about individual guidance
Speak with our team to find out whether guidance is appropriate for your situation.
WhatsApp ↗